Current Report Filing (8-k)
19 December 2019 - 10:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 16, 2019
Bellicum Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36783
|
|
20-1450200
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
2130 W. Holcombe Blvd., Ste. 800
Houston, TX
|
|
77030
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: 832-384-1100
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.01 per share
|
|
BLCM
|
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On December 16, 2019, Edmund P. Harrigan, M.D. notified Bellicum Pharmaceuticals, Inc.
(the Company) of his resignation from his position as a member of the Companys Board of Directors (the Board), including each committee of the Board on which he is a member, to be effective December 19, 2019.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Bellicum Pharmaceuticals, Inc.
|
|
|
|
|
Dated: December 19, 2019
|
|
|
|
By:
|
|
/s/ Richard A. Fair
|
|
|
|
|
|
|
Richard A. Fair
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Bellicum Pharmaceuticals (PK) (USOTC:BLCM)
Historical Stock Chart
From May 2024 to Jun 2024
Bellicum Pharmaceuticals (PK) (USOTC:BLCM)
Historical Stock Chart
From Jun 2023 to Jun 2024